Verifying…
Home / Drug A–Z / Cotrikris (Paediatric Oral) Suspension

Cotrikris (Paediatric Oral) Suspension

NAFDAC Reg. No. A11-100647 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Cotrikris (Paediatric Oral) Suspension
NAFDAC number
A11-100647
Active ingredient
Sulfamethoxazole; Trimethoprim
Strength
200 mg/5 mL; 40 mg/5 mL
Form
Suspension
Pack size
1 x 50 mL (in plastic bottle)
Manufacturer
Not listed
Applicant (holder)
Krishat Pharma Industries Limited
Approved
31 Jan 2024
Status
Active View on NAFDAC ↗
Registration valid to
30 Jan 2029
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Cotrikris (Paediatric Oral) Suspension is on the NAFDAC register with an active registration (A11-100647). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Cotrikris (Paediatric Oral) Suspension is used for

From the official U.S. FDA label for sulfamethoxazole, the active ingredient registered with NAFDAC.

What it is used for

To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. …

Possible side effects

The most common adverse effects are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS (SEE WARNINGS SECTION). Hematologic Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia, methemoglobinemia, eosinophilia. …

Do not use if

Sulfamethoxazole and trimethoprim tablets are contraindicated in patients with a known hypersensitivity to trimethoprim or sulfonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency. Sulfamethoxazole and trimethoprim tablets are contraindicated in pediatric patients less than 2 months of age. …

Warnings

Embryofetal Toxicity Some epidemiologic studies suggest that exposure to sulfamethoxazole and trimethoprim during pregnancy may be associated with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If sulfamethoxazole and trimethoprim is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazards to the fetus. …

Pregnancy & breastfeeding

Pregnancy While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell, 10 in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Cotrikris (Paediatric Oral) Suspension

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Cotrikris (Paediatric Oral) Suspension

What is in Cotrikris (Paediatric Oral) Suspension?

Cotrikris (Paediatric Oral) Suspension contains Sulfamethoxazole; Trimethoprim (200 mg/5 mL; 40 mg/5 mL), as suspension, according to its NAFDAC registration record.

Is Cotrikris (Paediatric Oral) Suspension registered with NAFDAC?

Yes. Cotrikris (Paediatric Oral) Suspension is listed on the NAFDAC register under registration number A11-100647, and its registration is active as of 5 November 2026.

Has Cotrikris (Paediatric Oral) Suspension been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Cotrikris (Paediatric Oral) Suspension in our automatically synced alert list.

How can I check that my pack of Cotrikris (Paediatric Oral) Suspension is genuine?

Run a free authenticity scan with the NAFDAC number A11-100647, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Cotrikris (Paediatric Oral) Suspension used for?

To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, th (Summarised from the official U.S. FDA label for sulfamethoxazole. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Cotrikris (Paediatric Oral) Suspension? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.